


הכינוס התלת שנתי ה- X של החברה הישראלית לגינקולוגיה אונקולוגית

יום חמישי

20 ביוני 2019, י"ז בסיון תשצ"ט

מלון "דניאל", הרצליה



The Israeli Society of
Gynecologic Oncology

החברה
הישראלית
לגינקולוגיה
אונקולוגית



ועד החברה:

פרופ' עפר גמר / ד"ר אילן ברוכים, יו"ר ברוטציה
פרופ' אלון בן-אריה, מזכיר
ד"ר מריו ביינר, גזבר
פרופ' צבי ואקנין
ד"ר דליה צורף
ד"ר שלומי שגיא

ועדת שיפוט תקצירים ועבודות פרס:

ד"ר יעקב קורח
ד"ר ענבר בן שחר
ד"ר בוריס צוקרמן

ועדת בחירות:

פרופ' טליה לוי, יו"ר
ד"ר אילן אטלס
ד"ר מיכאל וולודרסקי

יו"ר עבר של החברה הישראלית לגינקולוגיה אונקולוגית:

פרופ' יוסף מנצ'ר
פרופ' שאול ענתבי
פרופ' גלעד בן-ברוך
ד"ר חנוך לבבי
פרופ' עוזי בלר
פרופ' עמי פישמן
פרופ' עופר לביא
ד"ר יעקב קורח
פרופ' טלי לוי

Invited speakers

מרצים מוזמנים

Professor Philipp Harter

Philipp Harter, MD, PhD, has been working since 2011 as deputy Director at the Department of Gynecology & Gynecologic Oncology at Kliniken Essen Mitte in Essen (Germany). Prior to This he worked as senior physician at the Department of Gynecology & Gynecologic Oncology at the Dr. Horst Schmidt-Klinik (HSK) in Wiesbaden, Germany, where he Specialized for gynecologic oncology. Dr Harter is specialized In surgery and systemic therapy of gynecologic cancers. He is member of the German Society of Gynecology and Obstetrics (DGGG) , the European Society of Gynecological Oncology (ESGO), the German Cancer Society (DKG), The Arbeit gemeinschaft Gynäkologische Oncology (AGO), the Kommission Ovar of the AGO. Since 2004 he has been a member of the leading group of the AGO Study Group and is currently the speaker of the AGO Study Group. He is a representative of the AGO Study Group at the Gynecologic Cancer Intergroup (GCIG) and European Network for Gynecological Oncological Trial groups (ENGOT). He was chair of the Ovarian Cancer Committee of Gynecologic Cancer Intergroup (GCIG) from 2012 - 2016. Since 2019, he chairs the Gynecologic Cancer Academy (GCA) of ENGOT. Furthermore, he was and is the principal investigator for multiple national and international phase II and III trials including multiple surgical trials of the AGO Study Group.



Professor Iain McNeish

Professor Iain McNeish is Professor of Oncology and head of the Division of Cancer at Imperial College London. He is also Director of the Ovarian Cancer Action Research Centre at Imperial College. He trained in medicine at the University of Oxford from 1986 to 1992 and undertook junior medical jobs in Oxford and Glasgow from 1992 until 1995. He then did his PhD as an MRC Clinical Fellow at the University of Birmingham until 1998 and Was subsequently a Cancer Research UK Clinician Scientist From 1999 to 2007 at Imperial College London. From 2007 Until 2012, he was an MRC Senior Clinical Fellow and Professor Of Gynecological Oncology at Barts Cancer Institute, London and, from 2012 – 2017, Professor of Gynecological Oncology at the University of Glasgow. His lab focusses on developing novel therapies for ovarian cancer including gene and viral therapies, based upon improved understanding the fundamental biology of the disease. He is also a consultant medical oncologist at Hammersmith Hospital London. He is the current chair of the NCRI Gynecological Clinical Studies Group as well as chair of the Cancer Research UK Clinical Careers Committee.



הכינוס התלת-שנתי ה-X של החברה הישראלית לגינקולוגיה אונקולוגית

יום חמישי, 20 ביוני 2019, י"ז בסיון תשצ"ט, מלון "דניאל", הרצליה

תוכנית הכינוס

08:00 – 08:45 התכנסות, רישום, כיבוד קל וסיור בתערוכה

08:45 – 09:00 ברכות ודברי פתיחה

פרופ' אלון בן-אריה, יו"ר הועדה המארגנת

פרופ' טליה לוי, יו"ר ועדת הבחירות – הצגת תקנון הבחירות והמועמדים

פתיחת קלפי הבחירות – 09:15

09:00 – 10:00 **מושב א: הצגת עבודות מקוריות**

יו"ר: ד"ר גדי סבח, ד"ר רוני פרץ

FOX M1- MEDIATED CHANGES IN GENE EXPRESSION FOLLOWING NEOADJUVANT CHEMOTHERAPY ASSOCIATED WITH SURVIVAL IN HIGH-GRADE SEROUS OVARIAN CANCER

Roy Kessous MD¹, David Oceau², Liron Kogan MD², Patricia N. Tonin PhD^{4,5},
Ido Laskov MD², Kathleen Klein PhD^{2,3}, Celia M. T. Greenwood PhD^{2,3,4},
Manuela Pelmus MD⁶, Shannon Salvador MD², Susie Lau MD², Amber
Yasmeen PhD², Walter H. Gotlieb MD PhD²

¹Department of Obstetrics and Gynecology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel, ²Division of Gynecologic Oncology, Segal Cancer Center, Lady Davis Institute of Research, Jewish General Hospital, McGill University, Montreal, Canada, ³Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada, ⁴Cancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁵Departments of Medicine and Human Genetics, McGill University, Montreal, QC, Canada, ⁶Division of Pathology, Jewish General Hospital, Montréal, Canada

OVARIAN CANCER IN JEWISH AND ARAB PATIENTS TREATED IN NORTHERN ISRAEL

Ido Behar¹, Jamal Zaidan^{1,2}, Avishalom Sharon³, Ayelet Shai^{1,4}

¹Azrieli Faculty of Medicine, Bar Ilan University, Zefad, Israel, ²Oncology inst., Rivka Ziv Medical Center, Zafed, Israel, ³Gynecology Dept, Galilee Medical Center, Nahariya, Israel, ⁴Oncology Dept, Galilee Medical Galilee Medical Center, Nahariya, Israel

STATIN USE AND THE PROGNOSIS OF ENDOMETRIAL CANCER: AN ISRAELI GYNECOLOGIC ONCOLOGY GROUP STUDY

Dr. Yakir Segev^a, Prof Ofer Gemer^b, **Dr. Meirav Schmidt^a**, Dr. Limor Helpman^c, Dr Nasreen Hag-Yahia^c, Dr. Ram Eitan^d, Dr. Oded Raban^d, Dr. Zvi Vaknin^e, Prof. Alon Ben Arie^f, Dr. Amnon Amit^g, Prof. Tally Levy^h, Dr. Ahmed Namazov^b, Dr. Michael Voldarsky^b, Dr. Inbar Ben Shacharⁱ, Dr. Ilan Atlas^j, Dr. Ilan Bruchim^k, Prof. Ofer Lavie^e

^a Obstetrics and Gynecology, Carmel Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel, ^b Obstetrics and Gynecology, Barzilai Medical Center, Faculty of Health Sciences, Ben-Gurion University, Ashkelon, Israel, ^c Obstetrics and Gynecology, Meir Medical Center, Israel; Sackler School of Medicine, Tel-Aviv University, Israel, ^d Obstetrics and Gynecology, Rabin Medical Center, Sackler School of Medicine, Tel-Aviv University, Peta Tikva, Israel, ^e Obstetrics and Gynecology, The Yitzhak Shamir Medical Center. Tzrifin, Israel, affiliated with the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ^f Obstetrics and Gynecology, Kaplan Medical Center, Hebrew University, Rehovot, Israel, ^g Obstetrics and Gynecology, Rambam Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel, ^h Obstetrics and Gynecology, Wolfson Medical Center, Sackler School of Medicine, Tel-Aviv University, Holon, Israel, ⁱ Obstetrics and Gynecology, Ziv Medical Center, Bar Ilan University, Zefat, Israel, ^j Obstetrics and Gynecology, Poriya Medical Center, Bar Ilan University, Tiberia, Israel, ^k Obstetrics and Gynecology, Hillel Yaffe Medical Center, Rappaport Faculty of Medicine, Technion, Hadera, Israel

PROGNOSTIC VALUE OF PATHOLOGIC CHEMOTHERAPY RESPONSE SCORE IN OVARIAN CANCER PATIENTS AFTER NEOADJUVANT CHEMOTHERAPY

Michaan Nadav^{1,2}, Yoo Chong Woo², Lim Myong Cheol², Park Sang Yoon²

¹Lis Maternity Hospital, Tel Aviv Sourasky Medical center and Sackler School of Medicine, Tel Aviv University, Israel, ²Common Cancer Branch and Center for Uterine Cancer, National Cancer Center, Goyang, Republic of Korea

HORMONE REPLACEMENT THERAPY FOR BRCA-MUTATION CARRIERS: ATTITUDES OF ISRAELI HEALTH-CARE PROVIDERS BEFORE AND AFTER A BRIEF EDUCATIONAL INTERVENTION

Tamar Perri, MD,^{1,2} Yasmin Farhadian, MD,^{1,2} Eitan Friedman, MD PhD,^{2,3} Jacob Korach, MD,^{1,2}

¹Department of Gynecologic Oncology, Sheba Medical Center, 52621 Tel Hashomer, Israel; ²Sackler Faculty of Medicine, Tel Aviv University, 69978 Ramat Aviv, Israel; ³Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Sheba Medical Center, 52621 Tel Hashomer, Israel

NEUTROPHIL-TO-LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN ADVANCED STAGE OVARIAN CARCINOMA TREATED WITH NEOADJUVANT CHEMOTHERAPY

Lina Salman; Gad Sabah; Ariella Jakobson-Setton; Oded Raban; Effi Yeoshoua; Ram Eitan

Gynecologic Oncology Division, Helen Schneider Hospital for Women, Rabin Medical Center; Petah-Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

THE IGF1 SIGNALING PATHWAY EFFECT ON DENDRITIC CELL DIFFERENTIATION IN EPITHELIAL OVARIAN CANCER

Lina Somri-Gannam¹, Shilhav Meisel Sharon¹, Shay Hantisteanu¹, Mordechai Hallak^{1,2} and Ilan Bruchim^{1,2}

¹Gynecology Laboratory, Department of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Technion-Israel Institute of Technology, Hadera, Israel, ²Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel

AGE IS AN INDEPENDENT PREDICTOR OF OUTCOME IN ENDOMETRIAL CANCER PATIENTS: AN ISRAELI GYNECOLOGY ONCOLOGY GROUP COHORT STUDY

Nasreen Hag-Yahia¹, Ofer Gemer², Ram Eitan³, Oded Raban³, Zvi Vaknin⁴, Tally Levy⁵, Sofia Leytes⁵, Ofer Lavie⁶, Alon Ben-Arie⁷, Amnon Amit⁸, Ahmed Namazov², Michael Volodarsky², Inbar Ben-Shachar⁹, Ilan Atlas¹⁰, Ilan Bruchim¹¹, **Yfat Kadan**¹ and Limor Helpman^{1, a}

¹ Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar Saba, ² Barzilai University Medical Center, Faculty of Health Sciences, Ben-Gurion University, Ashkelon, ³ Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Petah Tikva, ⁴ Assaf Haroffe Medical Center, Sackler School of Medicine, Tel Aviv University, Zrifin, ⁵ Wolfson Medical Center, Sackler School of Medicine, Tel Aviv University, Holon, ⁶ Carmel Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, ⁷ Kaplan Medical Center, Hebrew University, Rehovot, ⁸ Rambam Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, ⁹ Ziv Medical Center, Bar Ilan University, Zefat, ¹⁰ Poriya Medical Center, Bar Ilan University, Tiberias, ¹¹ Hillel Yaffe Medical Center, Rappaport Faculty of Medicine, Technion, Hadera

מרצים אורחים 11:00 – 10:00

יו"ר: ד"ר אילן ברוכים, דר שלומי שגיא

Treatment of relapsed Ovarian Cancer – Surgery and systemic treatment
Prof. Philipp Harter

How to understand the genome complexity of high grade serous ovarian cancer and identify new biomarkers
Prof. Iain McNeish

כיבוד קף וסיוך בתצרכה 11:30 – 11:00

סיכום פעילות הוועד היוצא – ד"ר אילן ברוכים, פרופ' עופר גמר 11:40 – 11:30

מושב א: הצגת עבודות מקוריות 12:30 – 11:40

יו"ר: ד"ר יהודה בן דוד, ד"ר איילת שי

WHOLE POPULATION BRCA SCREENING IS COST EFFECTIVE IN ISRAEL, EVEN WITH VARYING PREVALENCE OF BRCA MUTATION

Michaan Nadav¹, Leshno Moshe², Safra Tamar², Meroz Rotem², Laskov Ido¹, Grisaru Dan¹

¹Lis maternity hospital, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

²Tel Aviv Sourasky medical center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

CLEARANCE OF HIGH-RISK HPV AFTER LLETZ HAS A HIGH PREDICTIVE VALUE OF ABSENCE OF RESIDUAL MALIGNANCY.....IN WOMEN WITH EARLY STAGE CERVICAL CANCER

Siegler Efraim¹, Goldberg Yael^{1,5}, Sabu Edmond^{2,5}, Shaked-Mishan Pninit³, Siegler Yoav⁴, Mazareb Salam², Lavie Ofer^{1,5}, Segev Yakir^{1,5}

Department of Obstetrics & Gynecology, Carmel Medical Center¹, Department of Pathology, Carmel Medical Center², Clinical Serology and Virology Laboratory, Carmel Medical Center³, Rambam Medical Center⁴, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology⁵, Haifa, Israel

DO OVARIAN CANCER PATIENTS WITH PRIMARY OR SECONDARY PLATINUM RESISTANCE HAVE SIMILAR RESPONSE TO SUBSEQUENT CHEMOTHERAPY – A RETROSPECTIVE COHORT STUDY

Aleohin Natalie, MD; Migdan Zohar, MD; Elyashiv Osnat, MD; Peled Ofri, MD; Ben Shem Erez, MD; Levy Tally, MD, MHA

Division of Gynecologic Oncology, Wolfson Medical Center, Holon; Sackler faculty of Medicine, Tel-Aviv University

DOES SENTINEL LYMPH NODE BIOPSY IN ENDOMETRIAL CANCER SURGERY HAVE AN IMPACT ON THE RATE OF ADJUVANT PELVIC RADIATION?

Yoav Brezinov^a, Tamar Katzir^a, Yael Naaman^a, Adela Yachnin^a, Natalia Oustinov^a, Ofer Gemer^b, Limor Helpman^c, Nasreen Hag-Yahia^c, Ram Eitan^d, Oded Raban^d, Zvi Vaknin^e, Sophia Leytes^f, Ofer Lavie^g, Amnon Amit^g, Tally Levy^f, Ahmed Namazov^b, Michael Voldarsky^b, Inbar Ben Shacharⁱ, Ilan Atlas^j, Ilan Bruchim^h, Alon Ben-Arie^a. An Israeli Gynecologic Oncology Group Study (IGOG)

^aKaplan Medical Center, Rehovot, affiliated to The Hebrew University, Jerusalem, ^bBarzilai Medical Center, Ashkelon, affiliated to Ben Gurion University, Beer-Sheva, ^cMeir Medical Center, Kfar Saba, affiliated to Tel Aviv University, Tel Aviv, ^dRabin Medical Center, Petah Tikva, affiliated to Tel Aviv University, Tel Aviv, ^eAssaf Haroffe Medical Center, Zrifin, affiliated to Tel Aviv University, Tel Aviv, ^fWolfson Medical Center, Holon, affiliated to Tel Aviv University, Tel Aviv, ^gRambam Medical Center, Haifa, affiliated to Technion, Haifa, ^hHillel Yaffe Medical Center, Hadera, affiliated to Technion, Haifa, ⁱZiv Medical center, Zefat, affiliated to Bar Ilan University, Ramat Gan, ^jPoria Medical Center, Tiberias, affiliated to Bar Ilan University, Ramat Gan

OVARIAN CANCER AND ENLARGED SUPRADIAPHRAGMATIC LYMPH NODES THE EFFECT OF SURGERY ON PATIENTS WITH STAGE III

Weitzner Omer, **Yagur Yael**, Kadan Yfat, Fishman Ami, Zissin Rivka, Ben Ezra Emili, Beiner Mario

Meir Medical Center, Clalit Health Services and Sackler School of Medicine, Tel Aviv University

FTIR SPECTROSCOPY OF GYNECOLOGIC CANCER TISSUES

I. Bruchim^{1,4*}, **R. Reens Carmel^{1,4}**, B. Z. Dekel², G. M. Groisman^{3,4}, M. Halak^{1,4}, D. Malonek²

¹Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel, ²Dept. of Electrical & Computer Engineering, Ruppin Academic Center, Emek Hefer, Israel, ³Department of Pathology, Hillel Yaffe Medical Center, Hadera, Israel, ⁴Technion Israel Institute of Technology, Haifa, Israel

THE ASSOCIATION BETWEEN ULTRASNOGRAPHIC ENDOMETRIAL THICKNESS AND SURVIVAL OF PATIENTS WITH ENDOMETRIAL CANCER: AN ISRAEL GYNECOLOGIC ONCOLOGY GROUP STUDY

Ahmet Namazov¹, Ofer Gemer¹, Nasreen Hag-Yahia², Ram Eitan³, Oded Raban³, Zvi Vaknin⁴, Sophia Leytes⁵, Ofer Lavie⁶, Alon Ben Arie⁷, Amnon Amit⁸, Tally Levy⁵, Michael Volodarsky¹, Inbar Ben Shachar⁹, Ilan Atlas¹⁰, Ilan Bruchim¹¹, Limor Helpman²

¹Barzilai University Medical Center, Faculty of Health Sciences, Ben-Gurion University, Ashkelon, ²Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar Saba ³Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Peta Tikva, ⁴Assaf Haroffe Medical Center, Sackler School of Medicine, Tel Aviv University, Zrifin, ⁵Wolfson Medical Center, Sackler School of Medicine, Tel Aviv University, Holon, ⁶Carmel Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, ⁷Kaplan Medical Center, Hebrew University, Rehovot, ⁸Rambam Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, ⁹Ziv Medical Center, Bar Ilan University, Zefat, ¹⁰Poriya Medical Center, Bar Ilan University, Tiberia, ¹¹Hillel Yaffe Medical Center, Rappaport Faculty of Medicine, Technion, Hedera

מרצים אורחים 13:30 – 12:30

יו"ר : פרופ צבי וקנין, דר מריו ביינר

The stratified treatment and immunotherapy in recurrent / metastatic endometrial and cervical cancer

Prof. Iain McNeish

Management of primary ovarian cancer PDS vs IDS, management of lymph nodes and Systemic treatment including PARP inhibitors maintenance treatment.

Prof. Philipp Harter

ברור גנטי וגנומי בחולות חדשות של סרטן שחלה 13:35 – 13:30

ד"ר אורה רוזנגרטן

ארוחת צהריים וסיור בתצפית 14:30 – 13:35

סגירת קלפי הבחירות – 14:00

DNA & RNA sequencing in gynecological malignancies 14:45 – 14:30

Sheba Medical Center- Dr Ronnie Shapira Frommer

הרצאה בחסות חברת טבע

15:30 – 14:45
מושב III: הצגת עבודות מקוריות
יו"ר: ד"ר אבי בן שושן, ד"ר דליה צורף

PALLIATIVE URINARY DIVERSION IN PATIENTS WITH MALIGNANT URETERIC OBSTRUCTION DUE TO GYNECOLOGIC CANCER

Tamar Perri ^{a,b,*,1}, **Elad Meller** ^{a,b,1}, Gilad Ben-Baruch ^{a,b}, Yael Inbar ^{b,c}, Sara Apter ^{b,c}, Lee Heyman ^{b,c}, Zohar Dotan ^{b,d}, Jacob Korach ^{a,b}

^a Department of Gynecologic Oncology, Sheba Medical Center, 52621 Tel Hashomer, Israel

^b Sackler Faculty of Medicine, Tel Aviv University, 69978 Ramat Aviv, Israel, ^c Department of Diagnostic Imaging, Sheba Medical Center, 52621 Tel Hashomer, Israel, ^d Department of Urology, Sheba Medical Center, 52621 Tel Hashomer, Israel

RETROPERITONEAL LYMPH NODE RECURRENCE OF EPITHELIAL OVARIAN CANCER: PROGNOSTIC FACTORS AND TREATMENT OUTCOME

Migdan Zohar, MD; Aleohin Natalie, MD; Elyashiv Osnat, MD; Peled Ofri, MD; Ben Shem Erez, MD; Levy Tally, MD, MHA

Division of Gynecologic Oncology, Wolfson Medical Center, Holon; Sackler faculty of Medicine, Tel-Aviv University

GRANOLOSA CELL TUMOR - HIGH PARA0AORTIC RECUMENCE

הצגת התקציר בוידיו

Ron Eitan, **Moshe Meshulam**, Effi Yeoshoua, Gad Sabah, Ariella Jakobson-Setton, Andre Nado

Beilinson, Rabin Medical Center, 39Jabotinski St., Petah Tikva 49100

IS THE EXTENT OF PELVIC LYMPHADENECTOMY IN THE STAGING OF ENDOMETRIAL CANCER ASSOCIATED WITH THE YIELD OF METASTATIC NODES? AN ISRAELI GYNECOLOGIC ONCOLOGY GROUP STUDY

Michael Voldarsky¹, Ofer Gemer¹, Limor Helpman², Nasreen Hag-Yahia², Ram Eitan³, Oded Raban³, Ofer Lavie⁴, Alon Ben Arie⁵, Amnon Amit⁶, Tally Levy⁷, Ahmed Namazov¹, Inbar Ben Shachar⁸, Ilan Atlas⁹, Ilan Bruchim¹⁰, Zvi Vaknin¹¹

¹Obstetrics and Gynecology, Barzilai Medical Center, Faculty of Health Sciences, Ben-Gurion University, Ashkelon, Israel, ²Obstetrics and Gynecology, Meir Medical Center, Israel; Sackler School of Medicine, Tel-Aviv University, Israel, ³Obstetrics and Gynecology, Rabin Medical Center, Sackler School of Medicine, Tel-Aviv University, Peta Tikva, Israel, ⁴Obstetrics and Gynecology, Carmel Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel.

⁵Obstetrics and Gynecology, Kaplan Medical Center, Hebrew University, Rehovot, Israel,

⁶Obstetrics and Gynecology, Rambam Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel, ⁷Obstetrics and Gynecology, Wolfson Medical Center, Sackler School of Medicine, Tel-Aviv University, Holon, Israel, ⁸Obstetrics and Gynecology, Ziv Medical Center, Bar Ilan University, Zefat, Israel, ⁹Obstetrics and Gynecology, Poriya Medical Center, Bar Ilan University, Tiberia, Israel, ¹⁰Obstetrics and Gynecology, Hillel Yaffe Medical Center, Rappaport Faculty of Medicine, Technion, Hedera, Israel, ¹¹Obstetrics and Gynecology, The Yitzhak Shamir Medical Center (formerly Assaf Harofeh Medical Center), Zerifin, Israel, affiliated to Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

MULTIPLE LINES OF CHEMOTHERAPY FOR PATIENTS WITH HIGH GRADE OVARIAN CANCER - PREDICTORS FOR RESPONSE AND EFFECT ON SURVIVAL

R. Kessous MD¹, Michel D. Wissing MD PhD^{2,3}, I. Laskov MD⁴, J. Abitbol⁴, J. Bitharas⁴, V.R. Agnihotram PhD^{2,3}, A. Yasmeen PhD⁴, S. Salvador MD⁴, S. Lau MD⁴, W.H. Gotlieb MD PhD⁴.

¹Department of Obstetrics and Gynecology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel, ² Department of oncology, McGill University, Montreal, QC, Canada, ³ Division of Cancer Epidemiology, McGill University, Montreal, QC, Canada, ⁴ Division of Gynecologic Oncology, Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, Canada.

MICROVESICLE PROTEOMIC PROFILING OF UTERINE LIQUID BIOPSY FOR OVARIAN CANCER EARLY DETECTION

Georgina D Barnabas¹, Keren Bahar-Shany², Stav Sapoznik², Limor Helpman^{3,4}, Yfat Kadan³, Mario Beiner³, Omer Weitzner⁵, Nissim Arbib⁵, Jacob Korach^{4,6}, Tamar Perri^{4,6}, Guy Katz⁶, Anna Blecher⁶, Benny Brandt⁶, Eitan Friedman^{4,7}, David Stockheim^{4,8}, Ariella Jakobson-Setton^{4,9}, Ram Eitan^{4,9}, Shunit Armon¹⁰, Hadar Brand^{2,4}, Oranit Zadok¹¹, Sarit Aviel-Ronen¹¹, Michal Harel¹, Tamar Geiger¹, **Keren Levanon^{2,4}**

¹ Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, ² Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan, ³ Division of Gynecologic Oncology, Meir Medical Center, Kfar Saba.

⁴ Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, ⁵ Department of Obstetrics and Gynecology, Meir Medical Center, Kfar Saba, ⁶ Department of Gynecologic Oncology, Chaim Sheba Medical Center, Ramat Gan, ⁷ The Susanne-Levy Gertner Oncogenetics Unit, Chaim Sheba Medical Center, Ramat Gan, ⁸ Department of Gynecology, Chaim Sheba Medical Center, Ramat Gan, ⁹ Department of Gynecologic Oncology, Rabin Medical Center, Petah Tikva, ¹⁰ Department of Obstetrics & Gynecology, Shaare Zedek Medical Center, Jerusalem.

¹¹ Department of Pathology, Chaim Sheba Medical Center, Ramat Gan

MSD Tumor board - "בוהן פתע" למתמחים בחסות חברת MSD 16:00 – 15:30
פרס נסיעה לכנס גינקו-אונקולוגי בחו"ל למתמחה שיטיב לענות

מנחה: פרופ' אמנון עמית
פאנל: פרופ' פיליפ הרטר, פרופ' תמר ספרא
הצגות: ד"ר עידו מיק, ד"ר סער אהרוני

חלוקת פרסים לעבודות המצטיינות 16:00
ד"ר יעקב קורח, יו"ר ועדת פרס

תוצאות בחירות
פרופ' טלי לוי, יו"ר ועדת בחירות

סיום

רשימת פוסטרים

Poster 1:

COMPREHENSIVE GERIATRIC ASSESSMENT IS CORRELATED TO OVERALL SURVIVAL AMONG GYNECOLOGIC ONCOLOGY PATIENTS

Michaan Nadav^{1,2}, Yoo Chong Woo², Lim Myong Cheol², Park Sang Yoon²

¹Lis Maternity Hospital, Tel Aviv Sourasky Medical center and Sackler School of Medicine, Tel Aviv University, Israel, ²Common Cancer Branch and Center for Uterine Cancer, National Cancer Center, Goyang, Republic of Korea

Poster 2:

PRE-OPERATIVE LEVELS OF CIRCULATING CELL-FREE DNA AS A RISK-ASSESSMENT TOOL IN ENDOMETRIAL CANCER

Tamar Perri^{1,2}, **Itamar Zilberman**^{1,2}, Amos duvdevani³, Jacob Korach^{1,2}

¹Gynecologic Oncology, Sheba medical Center, Ramat Gan, ²Tel-Aviv University, Sackler faculty of Medicine, Ramat-Aviv, ³Clinical Biochemistry and Pharmacology, Soroka University Medical Center, School of Medicine, Ben Gurion University of the Negev, Beer Sheva, Israel

Poster 3:

THE RISK OF CERVICAL CANCER IN WOMEN WITH CIN 2-3 IN PREGNANCY-TIME FOR REEVALUATION THE GUIDELINES

Efraim Siegler¹, Lena Mackuli¹, Ofer Lavie^{1,3}, Amnon Amit^{2,3}

,Zvi Vaknin^{4,5}, Yakir Segev^{1,3}

Departments of Obstetrics & Gynecology, Carmel Medical Center (1), Rambam Health Care Campus (2), Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa Israel (3), Department of Obstetrics and Gynecology, Assaf Harofe Medical Center (3), Sackler Faculty of Medicine, Tel Aviv University Tel Aviv (5), Israel

Poster 4:

CHEMOTHERAPY TOXICITY IN BRCA MUTATION CARRIERS UNDERGOING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY

Weitzner Omer, **Yagur Yael**, Kadan Yfat, Beiner Mario, Fishman Ami, Ben Ezra Emili, Amitai Komem Daphna, Helpman Limor

Meir Medical Center, Clalit Health Services and Sackler School of Medicine, Tel Aviv University

Poster 5:

SPECT/CT AND INTRA-OPERATIVE GAMMA-PROBE MAPPING FOR ENDOMETRIAL CANCER ARE NOT SUFFICIENT FOR BILATERAL SENTINEL NODE DETECTION

Tal Ori, MD; Grinstein Udi, MD; Peled Ofri, MD; Ben Shem Erez, MD;

Elyashiv Osnat, MD; Levy Tally, MD, MHA

Division of Gynecologic Oncology, Wolfson Medical Center, Holon; Sackler faculty of Medicine, Tel-Aviv University

Poster 6:

IONIZABLE LIPID NANOPARTICLES ARE EFFECTIVE AT PENETRATING THE CORE OF EPITHELIAL OVARIAN CANCER SPHEROIDS

Tal Ori, MD^{1,2}; Grinstein Ehud, MD^{1,2}; Ramishetti Srinivas, PhD²; Landesman-Milo Dalit², PhD; Peer Dan, PhD²; Levy Tally, MD, MHA^{1,2}

¹Division of Gynecologic Oncology, Wolfson Medical Center, Holon; ²School of Molecular Cell Biology and Biotechnology, Tel-Aviv University, Ramat Aviv, Tel-Aviv.

Poster 7:

**GYNECOLOGIC SARCOMAS IN ISRAEL, INCIDENCE AND SURVIVAL OF
Y. Brudner¹, G. Haran¹, A. Blecher¹, B.G. Silverman^{2,3}, M. Hallak¹, I. Bruchim¹**

¹Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, affiliated with the Technion, Israel Institute of Technology, Israel

²Israel National Cancer Registry, Israel Ministry of Health, ³Tel Aviv University Sackler School of Medicine

Poster 8:

**הקשר בין המיקרוביום הגניטלי לזיהום ב-HPV ונגעים טרום ממאירים של צוואר הרחם
עודד רב¹, לאה רשף², ליאת בנימין-שטראוס¹, אריאלה סיטון¹, גד סבח¹, אורי גופנא²,
רם איתן¹**

¹היחידה לגינקולוגיה אונקולוגית, מרכז רפואי רבין, קמפוס בילינסון, ²המחלקה למיקרוביולוגיה
וביוטכנולוגיה, אוניברסיטת תל אביב

Poster 9:

**CASE PRESENTATION – LYNCH SYNDROME, TWO PRIMARY CANCERS
OF OVARY AND UTERUS**

Shaked Lev-Ari

MD – Physician-resident in Oncology at Hadassah Medical centers, the Hebrew University
Jerusalem

Poster 10:

**DOES THE HISTOPATHOLOGIC RESPONSE POST NEOADJUVANT
CHEMOTHERAPY IN OVARIAN CANCER PATIENTS CORRELATE WITH
DISEASE OUTCOME?**

Raban Oded, Salman Lina, **Yeoshoua Effi**, Yanichkin Natalia, Sabah Gad,
Jakobson-Setton Ariella, Tsoref Dalia, Eitan Ram.

Beilinson, Rabin Medical Center, 39Jabotinski St., Petah Tikva 49100

Poster 11:

**BEVACIZUMAB FOR ADVANCED STAGE OVARIAN CARCINOMA: A
SINGLE CENTER EXPERIENCE**

Lina Salman; Erika Gandelsman; Gad Sabah; Ariella Jakobson-Setton; Daliah
Tsoref; Oded Raban; Effi Yeoshoua; Ram Eitan

Gynecologic Oncology Division, Helen Schneider Hospital for Women, Rabin Medical Center;
Petah-Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Poster 12:

**HOMOLOGOUS RECOMBINATION PATHWAY MUTATIONS IN FRESHLY
ISOLATED TUMOR CELLS FROM PATIENTS WITH OVARIAN CANCER
CORRELATE WITH OUTCOME**

Roy Kessous MD¹, David Oceau², Liron Kogan MD², Patricia N. Tonin PhD^{4,5},
Ido Laskov MD², Kathleen Klein PhD^{2,3}, Celia M. T. Greenwood PhD^{2,3,4},
Manuela Pelmus MD⁶, Shannon Salvador MD², Susie Lau MD², Amber
Yasmeen PhD², Walter H. Gotlieb MD PhD²

¹Department of Obstetrics and Gynecology, Soroka University Medical Center,
Ben-Gurion University of the Negev, Beer-Sheva, Israel, ²Division of Gynecologic Oncology,
Segal Cancer Center, Lady Davis Institute of Research, Jewish General Hospital, McGill
University, Montreal, Canada, ³Department of Epidemiology, Biostatistics and Occupational
Health, McGill University, Montreal, QC, Canada, ⁴Cancer Research Program, The Research
Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁵Departments of
Medicine and Human Genetics, McGill University, Montreal, QC, Canada, ⁶Division of
Pathology, Jewish General Hospital, Montréal, Canada

Poster 13:

CA125 REDUCTION RATES DURING NEOADJUVANT CHEMOTHERAPY ARE ASSOCIATED WITH CYTOREDUCTIVE RESULTS, PROGRESSION-FREE, AND OVERALL SURVIVAL IN PATIENTS WITH ADVANCED HIGH-GRADE OVARIAN CANCER

Roy Kessous MD^A, Michel D. Wissing MD PhD^{C,D}, Sabrina Piedimonte MDCM MSc. ^B, Jeremie Abitbol^B, Liron Kogan MD^B, Ido Laskov MD^B, Amber Yasmeen PhD^B, Shannon Salvador MD^B, Susie Lau MD^B, Walter H. Gotlieb MD PhD^B.

^ADepartment of Obstetrics and Gynecology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel, ^B Division of Gynecologic Oncology, Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, Canada, ^C Department of oncology, McGill University, Montreal, QC, Canada, ^D Division of Cancer Epidemiology, McGill University, Montreal, QC, Canada

Poster 14:

TUMOR BRCA1/2 MUTATIONS PREDICT OUTCOME IN PATIENTS WITH HIGH-GRADE SEROUS TUBO-OVARIAN CANCERS

Roy Kessous MD¹, David Oceau², Liron Kogan MD², Patricia N. Tonin PhD^{4,5}, Ido Laskov MD², Kathleen Klein PhD^{2,3}, Celia M. T. Greenwood PhD^{2,3,4}, Manuela Pelmus MD⁶, Shannon Salvador MD², Susie Lau MD², Amber Yasmeen PhD², Walter H. Gotlieb MD PhD².

¹Department of Obstetrics and Gynecology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel, ²Division of Gynecologic Oncology, Segal Cancer Center, Lady Davis Institute of Research, Jewish General Hospital, McGill University, Montreal, Canada, ³Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada, ⁴Cancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁵Departments of Medicine and Human Genetics, McGill University, Montreal, QC, Canada, ⁶Division of Pathology, Jewish General Hospital, Montréal, Canada

מזכירות הכינוס

דוא"ל: Oncogyn2019@target-conferences.com
טלפון: 03-7959603, פקס: 03-5175155



החברה הישראלית לאינקובואיה אונקולוגית מודנה לחברות
על צורתם ותמיכתם בפעילותה

Platinum

Roche

Gold

teva

AstraZeneca 

Silver


SANOFI

 MSD

MEDISON
Delivering Innovative Healthcare


NEOPHARM ISRAEL
NEOPHARM GROUP